NRX Pharmaceuticals, Inc. (NRXP)

3.49USD +1.75% (+0.06)

Over 6M: +101.7%

Style
Area Line Line with markers Steps Candles Hollow candles Bars

Candles and bars need the day’s open, high and low, and need room to be drawn in: past about a year of trading a body is thinner than a hairline, so those three offer the longest window that fits instead.

2 3 4
Mar Apr May Jun Jul Aug Sep

Financials Quarterly

Figures
Revenue Gross Profit Operating Income Cost of Revenue Operating Cash Flow Free Cash Flow Net Income

A share count and earnings a share are not here: neither is money, so neither can share this axis. Both have their own panel on All charts.

All charts ›
Q3 '25 — Revenue: 242K Q3 '25 — Net Income: -5.9M Q4 '25 — Revenue: 983K Q4 '25 — Net Income: 360K Q1 '26 — Revenue: 1.1M Q1 '26 — Net Income: -1.4M Q2 '26 — Revenue: 1.1M Q2 '26 — Net Income: -16.5M -16M -12M -8M -4M 0 4M
Q3 '25 Q4 '25 Q1 '26 Q2 '26
Revenue Free Cash Flow Net Income

How it scores

For a valuation multiple, the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

1.8
SBC / sales 12.9%
OE margin -622.0%
Oper. margin -586.2%
Accruals -10.8%
Gross margin 46.6%
Asset turnover 0.099×
EBITDA margin -580.4%
FCF margin -609.0%
OCF margin -582.6%
Profit margin -691.8%
ROA -68.7%
ROCE -6956.3%
OCF / EBIT —
ROE —
ROIC —

4 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

0.8
EV/Sales 35.8×
EV/OE -5.8×
P/C 5.5×
FCF yield -14.0%
Div. yield —
EV/EBIT —
EV/GP —
Fwd P/E —
P/B —
P/E —
PEG —

2 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

0.5
RPO / sales —
RPO growth —
Segment HHI —

0 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

3.8
ND/EBITDA 0.22
Current ratio 0.86×
Interest cover -17.4×
Debt payback 0.0 yr
F-score 5.1 pts
Cash runway 1.3 yr
Quick ratio 0.86×
Cash / Debt —
Debt / Eq —
Equity / Assets —
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

1.0
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —
Sales CAGR 4Y —
Sales Q/Q —
Sales/sh Y/Y —
Shares change —

1 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.